The following kinetic parameters were found in 36 children aged 0-13 years:
| 10 mg/kg one-time (n=18) [Rylance] | 3 mg/kg steady state twice daily (n=18) [Hoppu] | |
|---|---|---|
| Cmax | 6 ±1.9 mg/l | 2.2-2.3 µg/mL |
| Tmax | 2.2 ± 1.2 hours | 1.7-2.3 hours |
| t½ | 6.8 ± 1.6 hours | 3.7-5.4 hours |
| Vd | 2.24 ± 0.57 l/kg | 0.86-1.08 l/kg |
| Cl | 0.241 ± 0.079 l/kg/hour | 0.14-0.17 l/kg/hour |
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Uncomplicated urinary tract infections |
|---|
|
| Upper respiratory tract infection |
|---|
|
| Maintenance treatment for chronic and prophylaxis for recurrent urinary tract infections, prophylaxis for vesicoureteral reflux (VUR), neurogenic bladder, bladder emptying disorders and urinary tract obstruction |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Adjustment in renal impairment as specified:
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
The safety profile in children does not differ from the safety profile in adults. [SmPC]
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
fragile X chromosome associated with mental retardation in children [SmPC]
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
No information available on specific warnings and precautions in children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Intermediate-acting sulfonamides | ||
|---|---|---|
| J01EC02 | ||
| Combinations of sulfonamides and trimethoprim, incl. derivatives | ||
|---|---|---|
| J01EE01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.